Evidence map›Paper›PMID 36282501›Full record

ArticleJAMA network open2022

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.

Zachary H Strasser, Noah Greifer, Aboozar Hadavand, Shawn N Murphy, Hossein Estiri

Abstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. In-hospital mortality in patients admitted to Australian intensive care units with COVID-19 between 2020 and 2024.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Update on Omicron variant and its threat to vulnerable populations.Public health in practice (Oxford, England) · 2024
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. In Support of Universal Admission Testing for SARS-CoV-2 During Significant Community Transmission.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zachary H StrasserMGH Laboratory of Computer Science, Massachusetts General Hospital, Boston.
Noah GreiferInstitute for Quantitative Social Science, Harvard University, Cambridge, Massachusetts.
Aboozar HadavandCollege of Computational Science, Minerva University, San Francisco, California.
Shawn N MurphyMGH Laboratory of Computer Science, Massachusetts General Hospital, Boston.
Hossein EstiriMGH Laboratory of Computer Science, Massachusetts General Hospital, Boston.

Funding

Finding Genomic Profiles of COVID-19 Phenotypes from the EHRU01HG008685 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIZABETH W KARLSON, Matthew S Lebo · 2015 to 2026
$13.6M
Temporal Phenotypes and Risk Models for the Post-COVID Syndrome and its sub-typesR01AI165535 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Hossein Estiri, SHAWN N MURPHY · 2022 to 2026
$4.1M
NHGRI NIH HHS U01 HG008685NIAID NIH HHS R01 AI165535NLM NIH HHS L70 LM014127
6 · The paper itself

Abstract

Importance: The SARS-CoV-2 Omicron subvariant, BA.2, may be less severe than previous variants; however, confounding factors make interpreting the intrinsic severity challenging. Objective: To compare the adjusted risks of mortality, hospitalization, intensive care unit admission, and invasive ventilation between the BA.2 subvariant and the Omicron and Delta variants, after accounting for multiple confounders. Design, Setting, and Participants: This was a retrospective cohort study that applied an entropy balancing approach. Patients in a multicenter inpatient and outpatient system in New England with COVID-19 between March 3, 2020, and June 20, 2022, were identified. Exposures: Cases were assigned as being exposed to the Delta (B.1.617.2) variant, the Omicron (B.1.1.529) variant, or the Omicron BA.2 lineage subvariants. Main Outcomes and Measures: The primary study outcome planned before analysis was risk of 30-day mortality. Secondary outcomes included the risks of hospitalization, invasive ventilation, and intensive care unit admissions. Results: Of 102 315 confirmed COVID-19 cases (mean [SD] age, 44.2 [21.6] years; 63 482 women [62.0%]), 20 770 were labeled as Delta variants, 52 605 were labeled as the Omicron B.1.1.529 variant, and 28 940 were labeled as Omicron BA.2 subvariants. Patient cases were excluded if they occurred outside the prespecified temporal windows associated with the variants or had minimal longitudinal data in the Mass General Brigham system before COVID-19. Mortality rates were 0.7% for Delta (B.1.617.2), 0.4% for Omicron (B.1.1.529), and 0.3% for Omicron (BA.2). The adjusted odds ratio of mortality from the Delta variant compared with the Omicron BA.2 subvariants was 2.07 (95% CI, 1.04-4.10) and that of the original Omicron variant compared with the Omicron BA.2 subvariant was 2.20 (95% CI, 1.56-3.11). For all outcomes, the Omicron BA.2 subvariants were significantly less severe than that of the Omicron and Delta variants. Conclusions and Relevance: In this cohort study, after having accounted for a variety of confounding factors associated with SARS-CoV-2 outcomes, the Omicron BA.2 subvariant was found to be intrinsically less severe than both the Delta and Omicron variants. With respect to these variants, the severity profile of SARS-CoV-2 appears to be diminishing after taking into account various factors including therapeutics, vaccinations, and prior infections.

Indexed as

COVID-19SARS-CoV-2AdultCohort StudiesFemaleHumansNew EnglandRetrospective Studies

Identifiers

PMID36282501
PMCPMC9597387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.